NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Blood

• Publication date

  2012-11-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/blood-2013-03-488197PMID 23821658
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• NOTCH1 and SF3B1 mutations can be added to the hierarchical prognostic classification in chronic lymphocytic leukemia

  2013cited by this paper
• The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial.

  2013cited by this paper
• TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial.

  2013cited by this paper
• Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.

  2012cited by this paper
• NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL

  2012cited by this paper
• NOTCH1 mutations in CLL associated with trisomy 12.

  2012cited by this paper
• Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia.

  2012cited by this paper
• Risk categories and refractory CLL in the era of chemoimmunotherapy.

  2012cited by this paper
• Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation

  2011cited by this paper
• Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness.

  2011cited by this paper
• Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia

  2011cited by this paper
• SF3B1 and other novel cancer genes in chronic lymphocytic leukemia.

  2011cited by this paper
• Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia

  2011cited by this paper
• From pathogenesis to treatment of chronic lymphocytic leukaemia

  2010cited by this paper
• Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.

  2009cited by this paper
• Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up.

  2008cited by this paper
• Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia

  2004cited by this paper
• Results of First Salvage Therapy for Patients Refractory to a Fludarabine Regimen in Chronic Lymphocytic Leukemia

  2002cited by this paper
• bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 23, 2013. For personal use

  2001cited by this paper
• Genomic aberrations and survival in chronic lymphocytic leukemia.

  2000cited by this paper
• Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia.

  1999cited by this paper

• Prognostic significance of in patients with chronic lymphocytic leukemia: A meta-analysis

  2025influential citation
• SOHO State of the Art Updates and Next Questions | Impact of Biologic Markers on Outcomes With Novel Therapy in Chronic Lymphocytic Leukaemia.

  2024cites this paper
• Insights into genetic aberrations and signalling pathway interactions in chronic lymphocytic leukemia: from pathogenesis to treatment strategies

  2024cites this paper
• Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024.

  2024cites this paper
• Tumor mutational load is prognostic for progression to therapy among high-count monoclonal B-cell lymphocytosis

  2024cites this paper
• Understanding splenic B‐cell lymphoma/leukaemia with prominent nucleoli: Diagnosis, underpinnings for disease classification and future directions

  2024cites this paper
• Precision diagnostics in chronic lymphocytic leukemia: Past, present and future

  2023cites this paper
• Approach to relapsed CLL including Richter Transformation

  2023cites this paper
• NOTCH1 Signalling: A key pathway for the development of high-risk chronic lymphocytic leukaemia

  2022cites this paper
• AID in Chronic Lymphocytic Leukemia: Induction and Action During Disease Progression

  2021cites this paper
• Precision Diagnostics in Lymphomas - Recent Developments and Future Directions.

  2021cites this paper
• Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM)

  2021cites this paper
• Perspectives on Precision Medicine in Chronic Lymphocytic Leukemia: Targeting Recurrent Mutations—NOTCH1, SF3B1, MYD88, BIRC3

  2021cites this paper
• Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune) therapy

  2021cites this paper
• NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma, Version 4.2020

  2020cites this paper
• Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology.

  2020cites this paper
• Prevalence and Immunophenotypic Characteristics of Monoclonal B-Cell Lymphocytosis in Healthy Korean Individuals With Lymphocytosis

  2020cites this paper
• Clinical Value of NOTCH1 Mutations Detection among Chronic Lymphocytic Leukemia Patients

  2020cites this paper
• Tumor mutational load predicts time to first treatment in chronic lymphocytic leukemia (CLL) and monoclonal B‐cell lymphocytosis beyond the CLL international prognostic index

  2020cites this paper
• Emerging treatment options for patients with p53-pathway-deficient CLL

  2019cites this paper
• CLL with Del (17p)/TP53 Mutation

  2019cites this paper
• Studies of Bruton’s tyrosine kinase inhibitors in B-cell malignancies

  2018cites this paper
• The Genomic and Epigenomic Landscape of Chronic Lymphocytic Leukemia

  2018cites this paper
• THE SPECTRUM OF TP53, SF3B1, AND NOTCH1 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS EXPOSED TO IONIZING RADIATION DUE TO THE CHORNOBYL NPP ACCIDENT.

  2018cites this paper
• Analysis of the 3'UTR region of the NOTCH1 gene in chronic lymphocytic leukemia patients.

  2018cites this paper
• NOTCH1 Aberrations in Chronic Lymphocytic Leukemia

  2018cites this paper
• Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome

  2018cites this paper
• Combined somatic mutation and copy number analysis in the survival of familial CLL

  2018cites this paper
• Highly similar genomic landscapes in monoclonal B-cell lymphocytosis and ultra-stable chronic lymphocytic leukemia with low frequency of driver mutations

  2018cites this paper
• An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness

  2017cites this paper
• SF3B1 mutation is a prognostic factor in chronic lymphocytic leukemia: a meta-analysis

  2017cites this paper
• Trisomy 12 assessment by conventional fluorescence in-situ hybridization (FISH), FISH in suspension (FISH-IS) and laser scanning cytometry (LSC) in chronic lymphocytic leukemia.

  2017cites this paper
• New drug discovery approaches targeting recurrent mutations in chronic lymphocytic leukemia

  2017cites this paper
• Novel prognostic molecular factors: a quantum leap in the field of chronic lymphocytic leukemia.

  2017cites this paper
• Clinicopathological features and outcome of chronic lymphocytic leukaemia in Chinese patients

  2017cites this paper
• Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyond

  2016cites this paper
• Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets

  2016cites this paper
• Genomic Features: Impact on Pathogenesis and Treatment of Chronic Lymphocytic Leukemia

  2016cites this paper
• Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations

  2016cites this paper
• Genomic and transcriptomic sequencing in chronic lymphocytic leukemia

  2016cites this paper
• The mutational signature of chronic lymphocytic leukemia.

  2016cites this paper
• Refractory Chronic Lymphocytic Leukemia: A Therapeutic Challenge.

  2016cites this paper
• The molecular pathogenesis of chronic lymphocytic leukaemia

  2016cites this paper
• Chronic lymphocytic leukaemia.

  2016cites this paper
• Exploring next-generation sequencing in chronic lymphocytic leukemia

  2016cites this paper
• Applications of next-generation technologies in the diagnosis of haematological diseases and cancer

  2016cites this paper
• Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL.

  2015cites this paper
• Treating chronic lymphocytic leukemia with a combination of rituximab and alemtuzumab: a “successful couple,” but are they still relevant together?

  2015cites this paper
• Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.

  2015cites this paper
• NCCN Clinical Practice Guidelines in Oncology ( NCCN Guidelines ) ® Non-Hodgkin ’ s Lymphomas

  2015cites this paper
• NOTCH1 mutations are associated with low CD20 expression in Chronic Lymphocytic Leukemia: evidences for a NOTCH1­mediated epigenetic regulatory mechanism

  2015cites this paper
• Treatment of chronic lymphocytic leukemia with monoclonal antibodies, where are we heading?

  2015cites this paper
• Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting

  2015cites this paper
• Deciphering the molecular landscape in chronic lymphocytic leukemia: time frame of disease evolution

  2015cites this paper
• The complex interplay between cell-intrinsic and cell-extrinsic factors driving the evolution of chronic lymphocytic leukemia.

  2015cites this paper
• CHRONIC LYMPHOCYTIC LEUKEMIA: TAKING A BIG LEAP FORWARD Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia

  2015cites this paper
• Presence of multiple recurrent mutations revealed by targeted NGS confers poor trial outcome of relapsed / refractory CLL

  2015influential citation
• New insights into hematopoietic stem cell transplantation for chronic lymphocytic leukemia: a 2015 perspective.

  2015cites this paper
• Prognostic signature and clonality pattern of recurrently mutated genes in inactive chronic lymphocytic leukemia

  2015cites this paper
• Splice factor mutations and alternative splicing as drivers of hematopoietic malignancy

  2015cites this paper
• NOTCH1 mutations in chronic lymphocytic leukemia patients sufferers of Chornobyl NPP accident.

  2015influential citation
• The mystery of chronic lymphocytic leukemia (CLL): Why is it absent in Asians and what does this tell us about etiology, pathogenesis and biology?

  2015cites this paper
• Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia.

  2015cites this paper
• Clonal evolution in chronic lymphocytic leukemia: impact of subclonality on disease progression

  2015cites this paper
• Low‐dose alemtuzumab in refractory/relapsed chronic lymphocytic leukemia: Genetic profile and long‐term outcome from a single center experience

  2015cites this paper
• The genomic landscape of chronic lymphocytic leukaemia: biological and clinical implications

  2015cites this paper
• Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art

  2014cites this paper
• Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients

  2014cites this paper
• Prognostic and predictive factors in patients with chronic lymphocytic leukemia: relevant in the era of novel treatment approaches?

  2014cites this paper
• Targeted therapy and outcome in chronic lymphocytic leukemia

  2014cites this paper
• Novel prognostic gene mutations identified in chronic lymphocytic leukemia and their impact on clinical practice.

  2014cites this paper
• Staging and Prognostic Factors in Chronic Lymphocytic Leukemia: CurrentStatus

  2014cites this paper
• Targeted therapy and outcome in chronic lymphocytic leukemia

  2014cites this paper
• Characterisation of lens epithelium derived growth factor isoforms in chronic lymphocytic leukemia: Studies and significance

  2014cites this paper
• Chronic lymphocytic leukemia cells in lymph nodes show frequent NOTCH1 activation

  2014cites this paper
• Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia.

  2014cites this paper
• Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL.

  2014cites this paper
• cyclophosphamide prolongs progression-free survival in high-risk CLL Frontline low-dose alemtuzumab with fludarabine

  2014cites this paper
• chemo-refractoriness Genetic lesions associated with chronic lymphocytic leukemia

  2014cites this paper
• NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment

  2014cites this paper
• Recurrent mutations refine prognosis in chronic lymphocytic leukemia

  2014cites this paper
• Role of allogeneic transplantation in patients with chronic lymphocytic leukemia in the era of novel therapies: a review

  2014cites this paper
• NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment

  2014cites this paper
• Evolving understanding of the CLL genome.

  2014cites this paper
• Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness.

  2014cites this paper
• A New Era is Coming up in the Treatment of Chronic Lymphocytic Leukemia

  2014cites this paper
• Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile.

  2014cites this paper
• Advances in treating chronic lymphocytic leukemia

  2014cites this paper
• Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans

  2014cites this paper
• IX. Chronic lymphocytic leukaemia: New genetic markers as prognostic factors

  2013cites this paper
• Clinical implications of the molecular genetics of chronic lymphocytic leukemia

  2013cites this paper
• New boys in town: prognostic role of SF3B1, NOTCH1 and other cryptic alterations in chronic lymphocytic leukemia and how it works

  2013cites this paper